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Abstract
Aims/hypothesis Minimal evidence supports the efficacy of flash monitoring in lowering HbA1c. We sought to assess the impact
of introducing flash monitoring in our centre.
Methods We undertook a prospective observational study to assess change in HbA1c in 900 individuals with type 1 diabetes
following flash monitoring (comparator group of 518 with no flash monitoring). Secondary outcomes included changes in
hypoglycaemia, quality of life, flash monitoring data and hospital admissions.
Results Those with baseline HbA1c ≥58mmol/mol (7.5%) achieved amedian −7mmol/mol (interquartile range [IQR] −13 to −1)
(0.6% [−1.2 to −0.1]%) change in HbA1c (p < 0.001). The percentage achieving HbA1c <58mmol/mol rose from 34.2% to 50.9%
(p < 0.001). Median follow-up was 245 days (IQR 182 to 330). Individuals not using flash monitoring experienced no change in
HbA1c across a similar timescale (p = 0.508). Higher HbA1c (p < 0.001), younger age at diagnosis (p = 0.003) and lower social
deprivation (p = 0.024) were independently associated with an HbA1c fall of ≥5 mmol/mol (0.5%). More symptomatic (OR 1.9,
p < 0.001) and asymptomatic (OR 1.4, p < 0.001) hypoglycaemia was reported after flash monitoring. Following flash monitor-
ing, regimen-related and emotional components of the diabetes distress scale improved although the proportion with elevated
anxiety (OR 1.2, p = 0.028) and depression (OR 2.0, p < 0.001) scores increased. Blood glucose test strip use fell from 3.8 to 0.6
per day (p < 0.001). Diabetic ketoacidosis admissions fell significantly following flash monitoring (p = 0.043).
Conclusions/interpretation Flash monitoring is associated with significant improvements in HbA1c and fewer diabetic
ketoacidosis admissions. Higher rates of hypoglycaemia may relate to greater recognition of hitherto unrecognised events.
Impact upon quality of life parameters was mixed but overall treatment satisfaction was overwhelmingly positive.
Keywords Clinical Diabetes . Clinical diabetes . Continuous glucose monitoring . Devices . DKA . HbA1c . Human .
Hypoglycaemia . Psychological aspects
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Introduction
Flash glucose monitoring provides users with an intersti-
tial glucose value upon scanning a glucose sensor with a
reader device. It is similar to conventional continuous
glucose monitoring (CGM) in providing a 24 h glucose
trace and trend arrows to help predict rate of change of
glucose. However, unlike CGM, flash monitoring does
not provide alarm functions and, in contrast to most cur-
rent CGM, does not require calibration with blood glucose
measurements [1]. Flash monitoring was introduced in the
UK in 2015, although prior to November 2017 all use was
limited to individuals who self-funded the purchase of
glucose sensors. Until recently, therefore, flash monitor
use was typically limited to more affluent individuals,
with lower than average HbA1c [2]. Most evidence for
the effectiveness of flash monitoring in lowering HbA1c
comes from small uncontrolled studies [3] and the only
large randomised controlled study in type 1 diabetes was
limited to people with baseline HbA1c ≤58 mmol/mol
(7.5%). This study demonstrated that flash monitoring re-
duced hypoglycaemia without deterioration in HbA1c [4].
There is, therefore, a paucity of evidence assessing the
effectiveness of flash monitoring in a representative pop-
ulation of people with type 1 diabetes. We present the
largest prospective evaluation of the impact of flash mon-
itoring in people with type 1 diabetes, with respect to
change in HbA1c, hypoglycaemia, psychological symp-
toms, quality of life, flash monitoring data and hospital
admissions.
Methods
Study design and participants We conducted a prospective
observational study of the first 900 patients commenced on
National Health Service (NHS)-funded flash monitoring
(Freestyle Libre, Abbott, Witney, UK) in two University hos-
pital clinics (Royal Infirmary of Edinburgh [RIE] andWestern
General Hospital) during February and March 2018. Prior to
February 2018, flash monitor use was limited to those able to
self-fund the purchase of sensors. From February 2018 on-
wards, people with type 1 diabetes were eligible for NHS-
funded flash monitor use, conditional upon fulfilling all
Scottish Diabetes Group criteria, namely that they: (1) were
using intensive insulin therapy; (2) agreed to attend a flash
monitoring education session; (3) agreed to scan glucose
levels at least six times per day; (4) agreed to share glucose
data with their clinic; and (5) had attended a diabetes struc-
tured education programme or demonstrated equivalent dia-
betes self-management knowledge. In February 2018, all peo-
ple with type 1 diabetes attending our clinics (n = 2910) were
sent a letter detailing these criteria and, if eligible, how to
obtain NHS-funded sensors. All individuals who commenced
NHS-funded flash monitoring attended a 1 h education ses-
sion [5] and completed a form providing the start date and
extent of any previous self-funded flash monitor use.
An additional cohort of all individuals with type 1 diabetes
attending RIE clinics (where complete HbA1c data were avail-
able for each of the past 5 years) was also created (n = 1351),
for the purpose of tracking longitudinal changes in HbA1c, in
relation to exposure to flash monitoring. This included a large
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comparator population with no prior or current flash monitor-
ing exposure (n = 518) and also all RIE flash monitor users
from the main cohort (described above) where 5 continuous
years of HbA1c data were available. This study was entirely
observational (with no deviation from standard clinical care)
and ethics approval was not required.
Outcomes The primary outcome was change in HbA1c,
defined as the difference between HbA1c prior to com-
mencement of any flash monitoring and the next available
value after the flash monitoring education session. We
also report the proportion of individuals achieving the
Scottish HbA1c target (<58 mmol/mol [7.5%]) and UK
National Institute for Health and Care Excellence
(NICE) target (≤48 mmol/mol [6.5%]) [6]. We obtained
hospital admission and emergency department attendance
data for the 6 months following NHS-funded flash moni-
tor use and the corresponding 6 month period in the pre-
ceding 2 years. National prescribing database data were
obtained for collected prescriptions for glucose test strips
and sensors, over the same timescale described above.
HbA1c, admission and prescribing data are presented for
the entire cohort of flash monitor users from both partic-
ipating hospitals (n = 900). Scottish Index of Multiple
Deprivation 2016 (SIMD) rank and quintile were deter-
mined [7]. The structured education programme offered in
our centre is Dose Adjustment for Normal Eating
(DAFNE) [8] and previous participation was discerned
from our national clinic database system, SCI-Diabetes
(https://www.sci-diabetes.scot.nhs.uk). Mode of insulin
delivery (multiple daily injection [MDI] or continuous
subcutaneous insulin infusion [CSII]) was also obtained
from SCI-Diabetes.
Additional data were collected in the subgroup of flash
monitor users attending the RIE (n = 589): these included
change in BMI, clinic questionnaire data, online questionnaire
data and flash monitoring data. All individuals attending RIE
diabetes clinics are asked to complete a form at each atten-
dance (electronic supplementary material [ESM]
Questionnaire 1) which includes hypoglycaemia questions
(including Gold score and a modification of the Clarke assess-
ment [9]), frequency of self-monitoring of blood glucose
(SMBG), timing of bolus insulin and the Hospital Anxiety
and Depression Scale (HADS) [10]. We report changes in
hypoglycaemia and HADS score in those where paired pre-
and post-flash monitoring questionnaires were available. In
addition, all individuals attending RIE flash monitoring edu-
cation events were sent an online questionnaire invitation
1 month after attendance (ESMQuestionnaire 2). This includ-
ed questions on satisfaction with flash monitoring and a mod-
ified version of the diabetes distress scale (DDS) [11]. Flash
glucose data was obtained from the ‘LibreView’ portal
(Freestyle Libre).
Statistical analysis Data were largely non-normally distributed
(as determined by Shapiro–Wilk test) and are presented as me-
dian and interquartile range (IQR). Paired data were analysed
by Wilcoxon signed-rank test and unpaired data by Mann–
Whitney U test. Comparisons across multiple groups were
analysed by Kruskal–Wallis test. Categorical data were
analysed by χ2 or by McNemar test, when comparing paired
repeated measurements. Logistic regression analysis was per-
formed to identify predictors of HbA1c response. One-
proportion Z test was used to analyse change in modified
DDS score responses. Correlations were analysed using
Spearman’s rank correlation. A mixed effects model was used
to assess the interaction between time (2014–2018) and expo-
sure to flash monitoring on log-transformed HbA1c, and paired
Student’s t test was used to analyse difference in log-
transformedHbA1c between 2016 and 2018 for each flashmon-
itoring exposure group. Significance was accepted at p < 0.05.
All analyses were performed using RStudio version 1.0.153
(https://www.rstudio.com).
Results
Baseline characteristics Baseline characteristics are presented
in ESM Table 1. Of the 354 (39.3%) individuals who had a
history of previous flash monitoring self-funding, 64.0% re-
ported greater than 50% use prior to NHS funding. Flash
monitor use was commenced by 7.4% of self-funders in
2015, 29.9% in 2016, 56.6% in 2017 and 6.0% in 2018.
Change in HbA1c and BMI following flash monitor use The
median change in HbA1c, between the last value prior to flash
monitor use and the most recent value, was −4 mmol/mol
(IQR −10 to 0, p < 0.001) (−0.4% [−0.9 to 0]). In individuals
with baseline HbA1c >75 mmol/mol (9.0%), the median
change was −14 mmol/mol (IQR −22 to −7, p < 0.001)
(−1.3% [−2.0 to −0.6]). In those with baseline HbA1c 58–
75 mmol/mol (7.5–9.0%), the median change was −5 mmol/
mol (IQR −10 to −1, p < 0.001) (−0.5% [−0.9 to 0.1]). In those
with HbA1c <58 mmol/mol (7.5%) at baseline, the median
change was −1 mmol/mol (IQR −5 to 3, p = 0.06) (−0.1%
[−0.5 to 0.3]). In total, those with a starting HbA1c that did
not meet our national target (<58 mmol/mol [7.5%]) experi-
enced a median −7 mmol/mol (−0.6%) change in HbA1c (IQR
−13 to −1 mmol/mol [−1.2 to −0.1%], p < 0.001). The median
interval from baseline HbA1c to final HbA1c was 245 days
(IQR 182 to 330), with no significant correlation between this
interval and change in HbA1c (r 0.044, p = 0.244) (ESM Fig.
1). Baseline HbA1c and subsequent change in HbA1c was
strongly negatively correlated (r −0.479, p < 0.001) (Fig. 1).
Overall there was a 48.8% increase in those achieving an
HbA1c <58 mmol/mol (7.5%) and a greater than twofold re-
duction in those with HbA1c above 75 mmol/mol (9.0%)
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(p < 0.001, Fig. 2). The proportion of individuals achieving
the NICE target of ≤48 mmol/mol (6.5%) rose from 10.1%
to 18.7% (p < 0.001). HbA1c since commencement of flash
monitoring was not available in 17.4% (n = 157) of individ-
uals in this cohort. The only significant differences in individ-
uals with missing follow-up HbA1c were greater proportion of
men (20.4% vs 14.4% of women, p = 0.017) and more indi-
viduals using MDI (19.3% vs 12.4% CSII users, p = 0.016)
(full data in ESM Table 2). Compared with the corresponding
period the previous year, in the first 6 months following NHS-
funded flash monitor use, the median number of prescribed
(and collected) glucose test strip items (50 test strips per item)
fell from 14 (IQR 7 to 21) to 2 (IQR 0 to 6) (p < 0.001). This
equates to 3.8 test strips per day falling to 0.6 per day. A
sufficient number of sensors were collected by 86.5% of flash
monitor users to provide complete coverage over the first
6 months (from February or March 2018). Only 3.4% experi-
enced ≤50% sensor coverage across this same period.
Median BMI increased from 26.0 kg/m2 (IQR 23.4 to 29.0)
to 26.3 kg/m2 (23.5 to 29.8) after commencing flash
monitoring (median interval 15 months [IQR 5 to 39],
p < 0.001). Median BMI increase across a similar interval
(2016–2018) in 396 non-flash monitor users was 0.1 kg/m2
(IQR −0.8 to 1) (p = 0.027 comparing BMI change in flash
monitor vs non-flash monitor users).
Predictors of flash monitor use and HbA1c comparison with
non-flash monitor users Within the RIE type 1 diabetes pop-
ulation, those who had not used flash monitoring were older,
more likely to be male, had greater social deprivation and
were less likely to have an HbA1c <58 mmol/mol (7.5%) at
baseline (Table 1).
Trends in HbA1c were compared in every individual
with type 1 diabetes attending the RIE, assessing the influ-
ence of flash monitoring exposure. Those who had never
used flash monitoring and those who started NHS-funded
flash monitoring after the initial February and March 2018
sessions had significantly higher baseline HbA1c than
those with a history of self-funded flash monitor use and
those commencing flash monitoring for the first time in
February and March 2018 (Fig. 3). Between 2016 and
2018 there was a significant fall in HbA1c in all flash mon-
itoring exposed groups but no significant change in those
not using flash monitoring (Fig. 3 and ESM Table 3).
Predictors of fall in HbA1c following flash monitor use 48.1%
(361/750) individuals achieved an HbA1c reduction of
5 mmol/mol (0.5%) or greater following commencement of
flash monitoring. Univariate analysis identified younger age
at diagnosis (18 years [IQR 11 to 29] vs 20 years [12 to 24],
p = 0.03), higher baseline HbA1c (68 mmol/mol [60 to 78] vs
58 mmol/mol [51 to 65], p < 0.001) (8.4% [7.6 to 9.3] vs 7.5%
[6.8 to 8.1]) and prior SMBG fewer than four times per day
(67.7% vs 45.2%, p < 0.001) as predictive of a fall in HbA1c of
5 mmol/mol (0.5%) or greater. Age, diabetes duration, sex,
previous self-funding, SIMD quintile, CSII use and DAFNE
attendance were not associated with a greater likelihood of
achieving a 5 mmol/mol (0.5%) fall in HbA1c with flash mon-
itoring (ESM Table 4). Logistic regression analysis identified
higher baseline HbA1c (OR 1.07 [95% CI 1.05, 1.08] per
mmol/mol increment [0.1%]; p < 0.001) as a predictor of re-
sponse, whilst belonging to the lower three (most deprived)
quintiles of SIMD (OR 0.68 [95% CI 0.49, 0.95], p = 0.024)
and older age at diagnosis (OR 0.973 [95% CI 0.966, 0.993]
per year increment, p = 0.003) were independently associated
with non-response (full model in ESM Table 5). In a separate
model including low frequency of prior SMBG (<4/day), there
was a borderline independent association with response (OR
1.70 [95% CI 0.99, 2.93], p = 0.055) (ESM Table 6).
Ques t ionna i re data Frequency of symptomat i c
hypoglycaemia (defined as glucose <3.5 mmol/l) increased,
with those reporting two to three episodes per week or more
Fig. 1 Relationship between baseline HbA1c and subsequent change in
HbA1c following flash monitoring. The grey shading indicates the 95%
CI for the regression line. Spearman’s r −0.479, p<0.001
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Fig. 2 Change in HbA1c category pre- and post-flash monitor use;
p<0.001, McNemar test for change, in both the <58 mmol/mol (7.5%)
and the >75 mmol/mol (9.0%) categories. FM, flash monitoring
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rising from 25.8% to 48.4% (p < 0.001) following flash mon-
itor use (ESM Fig. 2). Similarly, the proportion of people
experiencing any asymptomatic hypoglycaemia (<3.5 mmol/
l) rose from 20.4% to 29.5% (p < 0.001) (ESM Fig. 3). No
significant change in severe hypoglycaemia was observed
(7.3% vs 8.8%, p = 0.499) although there was a non-
significant increase in the number of episodes where uncon-
sciousness or seizure occurred (2.1% vs 4.5%, p = 0.099). No
significant difference was observed in Gold score (2 [IQR 1 to
2] vs 2 [1 to 3], p = 0.104) and the proportion of people with
impaired awareness of hypoglycaemia (IAH, defined as Gold
score ≥4) did not change (12.5% vs 13.1%, p = 0.867), al-
though prior IAH resolved in 42.5% (17/40) of people follow-
ing flash monitor use.
Administration of bolus insulin at least 15 min before
meals increased from 9.3% to 36.2% following commence-
ment of flash monitoring (p < 0.001).
Median HADS depression scores increased from 1 (IQR 0
to 3) to 2 (1 to 5, p < 0.001) with the proportion of those with
an elevated score (>7) rising from 7.6% to 15.0% (p < 0.001).
In the 8.2% of individuals (26/317) with newly elevated
HADS depression score after flash monitoring commence-
ment, the only difference observed was lower SIMD rank
(2686 [IQR 1715 to 3959] vs 4857 [2884 to 6445], p < 0.001).
Median HADS anxiety scores increased from 4 (IQR 2 to 8)
to 5 (2 to 8, p = 0.030) and the proportion with an elevated score
rose from 24.9% to 30.9% (p = 0.028). HADS anxiety scores
that were newly elevated after commencing flash monitoring
developed in 12.3% (39/317) of people. This was associated
with younger age (38 [IQR 26 to 47] vs 47 [35 to 58] years, p =
0.002), shorter duration of diabetes (13 [7 to 24] vs 22 [12 to
33] years, p = 0.002), prior history of self-funding (17.4% vs
9.2%, p = 0.031) and CSII use (21.7% vs 9.0%, p = 0.002).
These hypoglycaemia and HADS data were obtained from
routinely collected clinic questionnaires. Paired pre- and post-
flash monitoring questionnaires were available in 56.7% of
eligible individuals (n = 334). Presence of paired question-
naire data was more likely in older individuals (45 years
[IQR 33 to 57] vs 41 years [29 to 51], p = 0.001), those with
lower baseline HbA1c (63 mmol/mol [55 to 70] vs 65 mmol/
mol [56 to 75], p = 0.023) (7.9% [7.2 to 8.6] vs 8.1% [7.3 to
9.00]) and prior DAFNE participants (62.8% vs 52.4%, p =
0.013) (ESM Table 7).
Table 1 Comparison of demographic and clinical features by exposure to flash monitoring
Variable Self-fund (n = 162) NHS FM (n = 250) Late NHS FM (n = 153) No FM (n = 518) P value
Age 42 (30 to 52) 49 (38 to 60) 47 (30 to 57) 54 (38 to 64) <0.001
Age at diagnosis 16 (10 to 26) 20 (11 to 32) 18 (11 to 29) 23 (12 to 36) <0.001
Duration of diabetes 22 (13 to 33) 24 (14 to 35) 22 (13 to 33) 24 (15 to 36) 0.254
Female (%) 51.2 53.7 43.8 42.3 0.021
SIMD 1 (%) 6.2 7.3 7.3 15.4
SIMD 2 (%) 16.3 20.7 22.0 28.3
SIMD 3 (%) 13.8 19.1 19.3 15.2
SIMD 4 (%) 16.3 20.3 18.7 16.6
SIMD 5 (%) 47.5 32.5 32.7 24.6 <0.001
CSII (%) 38.3 24.0 11.1 6.8 <0.001
HbA1c <58 mmol/mol (7.5%) 2016 (%) 35.2 34.4 30.1 25.1 0.016
Data are median (IQR) or %
Continuous variables are compared across all groups by Kruskal-Wallis test and categorical variables by χ2 test
Self-fund: individuals who self-funded purchase of flash monitor (FM) prior to taking up NHS-funded sensors in Feb/Mar 2018. NHS FM: individuals
whose first FM use was in Feb/Mar 2018 (i.e. no self-funded use). Late NHS FM: individuals whose first FM use was after Mar 2018 (i.e. no self-funded
use). No FM: Individuals with no previous or current FM use
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All individuals attending RIE flash monitoring education
events were invited to complete a single online questionnaire
which included a modified version of the DDS questionnaire,
where potential responses were: ‘much more of a problem’
(assigned a value of −2), ‘more of a problem’ (value = −1),
‘unchanged’ (value = 0), ‘less of a problem’ (value = 1) and
‘much less of a problem’ (value = 2). The median responses
were: 0 (IQR 0 to 0.3) for physician related distress, 0 (0 to
0.3) for interpersonal distress, 1 (0.4 to 1.4) for regimen-
related distress and 0.6 (0.2 to 1.0) for the emotional compo-
nent. Full results from the modified DDS are presented in
ESM Table 8. The percentage of respondents with a net im-
provement in total DDS (90.0%), regimen-related distress
(88.7%) and emotional distress (83.0%) were all significantly
greater than 50.0% (p < 0.001). Respondents were also asked
to provide a score from −5 (less control) to +5 (more control)
with respect to the overall effect of flash monitoring on diabe-
tes control; the median response was +5 (IQR 3 to 5). Of those
who responded to the questionnaire, 70.6% reported taking
their bolus insulin doses earlier in relation to meals following
commencement of flash monitoring. The online questionnaire
was completed by 54.1% of eligible individuals, with no de-
mographic or diabetes-related differences between respon-
dents and non-respondents (ESM Table 9).
Flash monitoring data When considering the entire cohort,
where any flash monitoring data were available (n = 166),
there were strong correlations with number of daily scans
and both final HbA1c (r −0.255, p < 0.001) and change in
HbA1c (r −0.279, p < 0.001). Paired flash monitoring data
(i.e. within 7 days of first flash monitor use and at least
1 month later) was available in 53 of a possible 362 individ-
uals with no prior self-funded flash monitor use. The only
significant difference between those for whom this informa-
tion was available and those for whom it was not was younger
age at diagnosis (16 years [IQR 10 to 24] vs 21 years [12 to
33], p = 0.013) (ESM Table 10). The median interval between
baseline and follow-up flash monitoring data was 6 months
(IQR 5 to 7). No differences were observed in time between
3.9 and 10.0 mmol/l glucose, time above 10 mmol/l, time
below 3.9 mmol/l , hypoglycaemic event number,
hypoglycaemic event duration or mean glucose (ESM
Table 11). The only significant difference was a fall in daily
flash monitoring scans from baseline to follow-up (13 [IQR 9
to 19] vs 10 [6 to 14], p < 0.001).
Hospital admission data There was a significant reduction in
admissions for diabetic ketoacidosis (DKA), falling from 10
to 2 episodes (p = 0.043) in the 6 months following NHS-
funded flash monitoring (compared with the corresponding
period 2 years earlier [2016]). No differences were noted in
the 6 months following NHS-funded flash monitoring with
respect to number of hospital admissions (p = 0.539), duration
of hospital admissions (p = 0.680) or emergency department
attendances (p = 0.449).
Discussion
We have demonstrated a significant and clinically important
reduction in HbA1c in people with type 1 diabetes following
flash monitor use. The clear temporal relationship between
flash monitoring commencement and fall in HbA1c, supported
by the absence of change in those who had not used flash
monitoring, suggests flash monitor use as the causal factor.
The magnitude of change in HbA1c is consistent with previ-
ously published reports assessing CGM, such as the
DIAMOND (−7 mmol/mol [0.6%]), GOLD (−5 mmol/mol
[0.5%]) and JDRF (−6 mmol/mol [0.6%]) studies [12–14].
The HbA1c change is also consistent with our previous small
uncontrolled study of flash monitoring outcomes where the
mean fall in HbA1c was 5 mmol/mol (0.5%) [3].
No individual factor is sufficiently predictive to preclude the
possibility of benefit in any particular group. However, these
data clearly suggest the largest HbA1c lowering benefits are
observed in those with higher HbA1c. Prescribing guidance in
the UK has often sought to limit flash monitor use to those who
monitor blood glucose most frequently, however these data
suggest this is illogical, as those who previously checked least
frequently had significantly greater likelihood of achieving an
HbA1c fall of 5 mmol/mol or greater. The greater likelihood of
HbA1c response in those belonging to more affluent SIMD
quintiles may represent a proxy for greater numeracy and data
interpretation skills within this group [15], although it is diffi-
cult to reconcile why younger age at diagnosis but not age or
duration of diabetes independently predicts response. As we
have previously demonstrated [3], flash monitor use resulted
in significant changes in bolus timing behaviour, which are
typically associated with improvements in HbA1c [16].
Self-reported episodes of both symptomatic and asymp-
tomatic hypoglycaemia increased following flash monitor
use. This is perhaps unsurprising as the additional glucose
information provided by flash monitoring is likely to have
highlighted hitherto unrecognised hypoglycaemia rather than
implying the development of greater hypoglycaemia per se.
The conventional wisdom that markedly increased
hypoglycaemia is the expected trade-off for improved HbA1c
has been challenged by recent evidence assessing the impact
of CGM [17]. Despite the additional information provided by
flash monitoring, there was no significant improvement in
awareness of hypoglycaemia. This study design cannot ex-
clude the possibility that flash monitoring reduces rates of
IAH, as it is possible that the 42.5% fall in those with pre-
existing IAH represents genuine improvement in awareness,
whilst some of the newly reported individuals with IAH may
simply reflect greater recognition of previously unrecognised
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hypoglycaemia. The only head-to-head comparison of flash
monitoring and CGM in IAH did, however, suggest benefit
only with the latter technology, suggesting real-time alarms
may be essential in this group [18].
Most investigations exploring the psychological impact of
CGM (specific evidence for flash monitoring does not yet
exist) have failed to demonstrate any significant change [19].
We found increased likelihood of elevated anxiety and depres-
sion scores following flash monitor use, although this conflict-
ed with snapshot data from the DDS and user evaluation of the
overall impact of flash monitoring, which was overwhelming-
ly positive. There do not appear to be any straightforward
predictors of where depression and anxiety are likely to wors-
en following flash monitoring. Newly elevated depression
score was associated with greater social deprivation (a
recognised risk factor for depression [20]) but not any specific
diabetes-related factors. The factors associated with newly
elevated anxiety scores (younger age, shorter diabetes dura-
tion, prior flash monitoring self-funding and CSII use) may
suggest a population with very high expectations for achiev-
ing tight glycaemic targets. These findings emphasise the im-
portance of setting realistic targets and providing support to
achieve them. The overall impression from user questionnaire
feedback (including the DDS) is that commencement of flash
monitoring has been a positive experience.
We chose to analyse only flash monitoring data from people
with no prior history of flashmonitor use and onlywhen this was
available within the first 7 days of use, as it is known that flash
monitor data changes within days of commencement [4]. As this
was a ‘real-world’ assessment, we did not have the benefit of any
blinded flash monitoring data prior to commencement.
Predictably, therefore, we did not find any differences in key
glycaemic parameters. A previous study demonstrated a strong
correlation between more flash monitoring scanning and lower
estimated HbA1c [21]; in addition, we have shown increased
scanning is prospectively associated with fall in HbA1c.
A recent ‘real-world’ assessment demonstrated a sig-
nificant reduction in hospitalisation following commence-
ment of CGM [22], although this cohort included a very
high prevalence of IAH. Overall, we were unable to detect
any significant difference in total hospital admissions and
emergency department attendances in the first 6 months
after flash monitoring commencement; this may be ex-
plained by relatively low baseline admission rates in this
young population. The number of individuals presenting
with DKA was also small, but we did observe a signifi-
cant reduction in hospital admissions for this indication.
Although this is potentially important, caution should be
exercised in extrapolating these findings to people with
recurrent DKA admissions as this study cohort has differ-
ent clinical and demographic characteristics [23].
Our study has a number of key strengths, most notably the
cohort size which is, to our knowledge, the largest prospective
assessment of flash monitoring outcomes described to date.
We have also been able to present comprehensive longitudinal
HbA1c data, including a large comparator population with no
flash monitoring, making the observed effects likely to be
attributable to flash monitoring. Due to scrupulous recording
of previous self-funded flash monitoring start dates, we have
been able to avoid missing important early changes in HbA1c
in those who self-funded prior to NHS funding. Beyond
HbA1c results, we have been able to assess effects across a
range of parameters important to individuals with diabetes
(including hypoglycaemia and quality of life data), through
routinely collected clinic data. Unlike many randomised con-
trolled trials, this population is likely to be substantially more
representative of usual clinical practice.
This study is open to the typical criticisms of observa-
tional methodology, in particular the possibility of unmea-
sured confounders and the potential for bias in relation to
missing follow-up data. To limit the potential for bias we
have assiduously reported the characteristics of those with
incomplete follow-up data and find little to support the
contention that this has significantly skewed the reported
findings (i.e. no differences in factors important in
predicting fall in HbA1c). Arguably a coincident advance
in diabetes care could have accounted for the observed im-
provement but no such change was introduced to our centre
in the past 2 years, and whole clinic data clearly demon-
strate the improvement in HbA1c being limited to flash
monitor users. The findings of this study are not necessarily
generalisable to everyone with type 1 diabetes, as we report
significant differences in the characteristics of flash moni-
tor users and non-users. However, given our relatively lib-
eral eligibility criteria for flash monitoring commencement,
they are likely to be generalisable to the population of peo-
ple who would seek to use flash monitoring.
Conclusions
Flash monitoring is associated with substantial reductions in
HbA1c, particularly in those with higher HbA1c prior to use.
Although user satisfaction is very high, there are potentially
issues around hypoglycaemia and psychological distress, at
least in the early phase of treatment intensification. The ob-
served fall in DKA admissions is promising and requires val-
idation in larger cohorts. It is essential that evidence gathering
in the field of glucose monitoring is responsive to the rapid
and accelerating rate of change, to ensure potential benefits are
realised early and by the largest possible number of people.
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